April 7, 2016
Pfizer Inc. and IBM have announced a first-of-its-kind research collaboration for developing state-of-the-art remote monitoring solutions in order to transform how clinicians deliver care to patients suffering from Parkinson’s disease. This experimental approach will depend on a system of mobile devices, sensors, and machine learning for providing real-time, around-the-clock disease symptom information to researchers and clinicians. The eventual goal is to obtain a better understanding of a patient’s disease progression and medication response, which will help inform treatment decisions and clinical trial design, while also speeding up developing new therapeutic options.
In particular, Parkinson’s disease needs ongoing adjustment to medication depending on the response of the patient and progression of the disease. This collaboration between IBM and Pfizer seeks to create a holistic view of a patient’s well-being by seeking to measure a variety of health indicators accurately, including dyskinesia, motor function, cognition, sleep and daily activities, like grooming, eating, and dressing. Insights from these data could help clinicians understand the effect of a patient’s medication as the disease progresses. This will also enable them to help optimize the patient’s treatment regimen as required. Researchers will also have the insights and real-world evidence needed to help accelerate potential new and better therapies using data generated through the system.
“We have an opportunity to potentially redefine how we think about patient outcomes and 24/7 monitoring, by combining Pfizer’s scientific, medical and regulatory expertise with IBM’s ability to integrate and interpret complex data in innovative ways. The key to our success will be to deliver a reliable, scalable system of measurement and analysis that would help inform our clinical programs across important areas of unmet medical need, potentially accelerating the drug development and regulatory approval processes and helping us to get better therapies to patients, faster,” said Mikael Dolsten, M.D., Ph.D., President of Pfizer Worldwide Research and Development.